---
title: "letter multicancer early detection tests"
year: 2024
month: 02
journal: "American Family Physician"
volume: "109-110"
issue: "02"
pages: ""
doi: ""
pmid: ""
source: "PDF Extraction"
pdf_available: true
original_pdf: "2024-02-letter-multicancer-early-detection-tests.pdf"
extracted_date: "2025-08-10"
keywords: []
evidence_level: ""
clinical_significance: ""
---

# letter multicancer early detection tests

                                               Letters to the Editor
Further Discussion Regarding Multicancer Early                                    References
Detection Tests                                                                     1. Doubeni CA, Castle PE. Multicancer early detection:​a promise yet to be
                                                                                       proven. Am Fam Physician. 2023;​107(3):​224-225.
                                                                                    2. Schrag D, Beer TM, Dilaveri CA, et al. PATHFINDER:​a prospective
To the Editor: We would like to comment on several state-                              study of a multi-cancer early detection blood test. ESMO Congress,
ments in the editorial on multicancer early detection tests                            Paris. September 11, 2022. Accessed November 15, 2023. https:​//
by Drs. Doubeni and Castle.1                                                           grail.com/wp-content/uploads/2022/09/Schrag_903O_ESMO-2022_
                                                                                       Pathfinder-Main_Proferred-Paper-Oral-Presentation.pdf
   The editorial states that performance characteristics of
                                                                                    3. Lennon AM, Buchanan AH, Kinde I, et al. Feasibility of blood testing
these tests are unclear for people in primary care. Two stud-                          combined with PET-CT to screen for cancer and guide intervention.
ies assessed multicancer early detection tests in average-risk                         Science. 2020;​369(6499):​eabb9601.
populations: the PATHFINDER study in 6,662 asymptom-                                4. Chen X, Dong Z, Hubbell E, et al. Prognostic significance of blood-
                                                                                       based multi-cancer detection in plasma cell-free DNA. Clin Cancer Res.
atic adults and the DETECT-A study in 10,000 women.2,3                                 2021;​27(15):​4221-4229.
PATHFINDER reported a specificity of 99.5% and a positive                           5. Ahlquist DA. Universal cancer screening:​revolutionary, rational, and
predictive value of 43%.2 The DETECT-A study, based on                                 realizable. NPJ Precis Oncol. 2018;​2:​23.
two blood tests, reported a specificity of 98.9% and a posi-                       6. Neal RD, Johnson P, Clarke CA, et al. Cell-free DNA-based multi-cancer
tive predictive value of 19.4%.3                                                      early detection test in an asymptomatic screening population (NHS-
                                                                                      Galleri):​design of a pragmatic, prospective randomised controlled trial.
   Furthermore, the editorial states that multicancer early                           Cancers (Basel). 2022;​14(19):​4818.
detection tests have not been studied to distinguish indolent
from lethal lesions. A study by Chen, et. al, showed that one
of two prospectively studied multicancer early detection                          In Reply: We thank Drs. Raoof and Klein for their com-
tests preferentially detects aggressive cancers.4                                 ments. The PATHFINDER and DETECT-A studies were
   The editorial continues by stating that individual cancers                     feasibility investigations and not designed for accurately
are rare and that most people undergoing screening will not                       assessing sensitivity and specificity.1,2 Sensitivity and spec-
benefit and are at risk of potential harms. This highlights the                   ificity determinations require establishing the presence or
statistical value of multicancer early detection tests: the uti-                  absence of cancer with a gold standard test administered to
lization of aggregate prevalence. Tests for multiple cancers                      all participants at the same time as the multicancer early
have a lower number needed to screen and a higher positive                        detection test, which neither study did.1 In both studies,
predictive value than a screening test for a single cancer type.5                 differential verification, selection, or spectrum biases would
   The editorial states that screening and detection during                       overestimate test accuracy and limit generalizability.3,4 The
the occult preclinical phase can create an illusion of longer                     PATHFINDER study included people with hereditary can-
survival. Lead-time bias is addressed by randomized con-                          cer predisposition and history of cancer; therefore, positive
trolled trials such as the ongoing NHS-Galleri trial, which                       predictive values would be lower in a general screening pop-
includes more than 140,000 patients.6                                             ulation than inferred from that study. The sample was also
Sana Raoof, MD, PhD                                                               fairly homogeneous (92% White participants). These stud-
New York, N.Y.                                                                    ies are useful for establishing feasibility but unsuitable for
raoofs@mskcc.org                                                                  establishing accuracy or clinical utility in primary care.
Eric A. Klein, MD                                                                    Tests with high specificity tend to have high false-
Cleveland, Ohio                                                                   negative rates. The sensitivity reported for CANCERSEEK
                                                                                  in the DETECT-A study was 27%.2 Current multicancer
Author disclosure: Dr. Raoof reports serving as a speaker, con-
                                                                                  early detection tests have lower sensitivity for earlier-stage
sultant, or advisory board member for Verily Life Sciences, Exact
Sciences, GRAIL, GLG, PRIMED, and AstraZeneca. Dr. Klein                          cancers, which are the main targets of screening. Differen-
reports current employment with GRAIL.                                            tiating cancer precursors or early cancers that will be fatal
                                                                                  in a person’s lifetime from indolent lesions that are nonfatal
                                                                                  is the goal of clinical prevention.5 Those questions cannot
  Email letter submissions to afplet@aafp.org. Letters should                     be answered by a study such as Chen, et al., that used previ-
  be fewer than 400 words and limited to six references,                          ously diagnosed cancer cases.
  one table or figure, and three authors. Letters submitted                          Screening in clinical prevention is a series of care pro-
  for publication in AFP must not be submitted to any other
                                                                                  cesses that extend beyond performing the test.4 Although
  publication. Letters may be edited to meet style and space
  requirements.                                                                   combining outcomes across all detectable cancers could
  This series is coordinated by Kenny Lin, MD, MPH, deputy
                                                                                  yield higher statistical power for a given sample, the effec-
  editor.                                                                         tiveness of screening is not based solely on the ability to
                                                                                  detect cancer, but on the ability to prevent premature

104   American
 Downloaded  from Family   Physician
                  the American   Family Physician website at www.aafp.org/afp.           © 2024 American Academy
                                                                                  Copyright
                                                                    www.aafp.org/afp                                     of Family
                                                                                                                     Volume    109,Physicians.
                                                                                                                                     Number For2 the
                                                                                                                                               ◆     private, non-
                                                                                                                                                  February    2024
 commercial use of one individual user of the website. All other rights reserved. Contact copyrights@aafp.org for copyright questions and/or permission requests.
                                                           LETTERS TO THE EDITOR


death from cancer.6 For some cancers (i.e., ovarian cancer                      conducted to add more data to the literature.4,5 Although
and pancreatic cancer), studies have shown that screening                       low-dose naltrexone shows promise in relieving pain symp-
results in net harm or does not demonstrate a mortality                         toms for people with fibromyalgia, a challenge is its limited
benefit. Multicancer early detection tests should be studied                    availability. Currently, oral naltrexone is available only in
to demonstrate the ability to decrease the risk of dying from                   50-mg tablets. Compounding pharmacies may be able to
an individual cancer or multiple cancers.1                                      create low-dose naltrexone, but insurance coverage presents
   We agree that randomized controlled trials are the ideal                     another challenge. After discussing the potential benefits
to demonstrate whether multicancer early detection tests                        and risks, the patient decided to try one-half of the 50-mg
provide more benefits than harms, and we look forward to                        tablet and found some relief.
the results of the NHS-Galleri study and others. Such stud-                     Manasa Irwin, MD
ies should be designed and powered to show the effect on                        Monroeville, Pa.
mortality and the harms of testing, and need many years of                      manasa.irwin@ahn.org

follow-up. We need such evidence to support using multi-                        Sarah Winter, PharmD
cancer early detection tests in routine screening of asymp-                     Monroeville, Pa.
tomatic people.1                                                                Author disclosure: No relevant financial relationships.
Chyke A. Doubeni, MD, MPH
Columbus, Ohio                                                                  References
chyke.doubeni@osumc.edu                                                          1. Winslow BT, Vandal C, Dang L. Fibromyalgia: diagnosis and manage-
                                                                                    ment. Am Fam Physician. 2023;107(2):137-144.
Philip E. Castle, PhD, MPH                                                       2. Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose
Rockville, Md.
                                                                                    naltrexone in the management of chronic pain and inflammation in
                                                                                    multiple sclerosis, fibromyalgia, Crohn’s disease, and other chronic pain
References                                                                          disorders. Pharmacotherapy. 2018;38(3):382-389.
 1. Doubeni CA, Lau YK, Lin JS, et al. Development and evaluation of safety      3. Kim PS, Fishman MA. Low-dose naltrexone for chronic pain: update and
    and effectiveness of novel cancer screening tests for routine clinical          systemic review. Curr Pain Headache Rep. 2020;24(10):64.
    use with applications to multicancer detection technologies. Cancer.        4. Bruun KD, Amris K, Vaegter HB, et al. Low-dose naltrexone for the
    2022;​1 28(suppl 4):​883-891.                                                  treatment of fibromyalgia: protocol for a double-blind, randomized,
 2. Doubeni CA. Medscape. Multi-cancer early detection:​evaluating the             placebo-controlled trial. Trials. 2021;22(1):804.
    progress and promise for the cancer screening future. Do you know            5. Colomer-Carbonell A, Sanabria-Mazo JP, Hernández-Negrín H, et al.
    how to talk to your patients about multi-cancer early detection tests?          Study protocol for a randomised, double-blinded, placebo-controlled
    Accessed July 12, 2023. https:​//www.medscape.org/viewarticle/993677            phase III trial examining the add-on efficacy, cost-utility and neurobi-
 3. Mulherin SA, Miller WC. Spectrum bias or spectrum effect? Subgroup              ological effects of low-dose naltrexone in patients with fibromyalgia
    variation in diagnostic test evaluation. Ann Intern Med. 2002;​1 37(7):​        (INNOVA study). BMJ Open. 2022;12(1):e055351.
    598-602.
4. Marshall RJ. Validation study methods for estimating exposure propor-
   tions and odds ratios with misclassified data. J Clin Epidemiol. 1990;​       Editor’s Note: This letter was sent to the authors of
   43(9):​941-947.                                                               “Fibromyalgia: Diagnosis and Management,” who declined to
 5. Doubeni CA. Precision screening for colorectal cancer:​promise and           reply.
    challenges. Ann Intern Med. 2015;​163(5):​390-391.
6. Doubeni CA, Levin TR. In screening for colorectal cancer, is the FIT right
   for the right side of the colon? Ann Intern Med. 2018;​169(9):​650-651.
                                                                                Corrections
                                                                                Incorrect Grading Scale. In the article “Bell Palsy: Rapid
Low-Dose Naltrexone: A Possible Option                                          Evidence Review” (April 2023, p. 415), one of the grades in
for Fibromyalgia                                                                the House-Brackman scale for classifying symptom severity
                                                                                of Bell palsy was inadvertently omitted in the right column
To the Editor: We want to thank Dr. Winslow and col-                            of page 416. The last two grades should have read as follows:
leagues for their excellent review of fibromyalgia.1 A patient                     • Grade V, severe symptoms: only slight, barely noticeable
recently presented to our practice who was taking recom-                        facial movement, asymmetric facial appearance, forehead
mended medications for fibromyalgia without much relief.                        cannot move, incomplete eyelid closure, mouth has only
The patient approached us about using low-dose naltrexone                       slight movement.
(Revia). A PubMed search showed that low-dose naltrexone                           • Grade VI, total paralysis: no facial movement.
(1 to 5 mg) has been used off-label to treat inflammation and                      The online version of this article has been corrected.
pain in fibromyalgia, multiple sclerosis, and Crohn disease.2
The mechanism of action is the modulation of neuroinflam-                       Table Columns Switched. In the article “Growth Faltering
mation, specifically, the release of inflammatory chemicals                     and Failure to Thrive in Children” (June 2023, p. 597), the
in the central nervous system and the modulation of glial                       information in the “Water (oz)” and “Formula” columns was
cells.3 Randomized, placebo-controlled trials are being                         inadvertently switched in the “Liquid Formula” section of

February 2024 ◆ Volume 109, Number 2                            www.aafp.org/afp                                     American Family Physician 105
                                             LETTERS TO THE EDITOR
                                            FIGURE 2

Table 4 (p. 601). Also, in the last sen-                         Arterial location of the                         Location on imaging
tence of the first paragraph of the Diag-                       aneurysm and incidence                            where blood collects
nosis section (p. 598), Bell palsy was




                                             © Dave Klemm
inadvertently listed instead of cerebral
palsy. The sentence should have read,
“Adjusted growth charts are avail-
able for children with conditions such
as cerebral palsy, Down syndrome,
Turner syndrome, and cri du chat syn-                                                    Anterior
drome, but these are based on smaller                                                   communi-
data samples.” The online version of the                                               cating artery
article has been corrected.

Incorrect Statistic. In the article “Pre-
venting CVD in Women: Common                Anterior communicating artery (30% to 35%)                       Interhemispheric hemorrhage
Questions and Answers” (December
2023, p. 595), the numbers of cardio-
                                             © Dave Klemm




                                                                    Basilar apex
vascular events occurring in relation
to age at onset of menopause were
inadvertently listed in the wrong order                                                                  Prepontine
                                                                                                           cistern
in the first paragraph of the Evidence
Summary in the Menstrual Charac-
teristics section (p. 597). The second                                                                                                    Third
sentence of the paragraph should have                                                                                                   ventricle
read, “Compared with menopause
                                                                                               Pons
onset at 55 years or older, CVD events
occur more often in those who have an
earlier onset, with 2.6 events per 1,000
person-years for onset at 45 to 49 years
of age, 3 events per 1,000 person-years                      Basilar apex (5%)                Prepontine or third ventricular hemorrhage
for onset at 40 to 45 years of age, and 4
                                             © Dave Klemm




events per 1,000 person-years for onset
                                                                                              Internal
before 40 years of age.” The online ver-                                                      carotid
sion of the article has been corrected.                                                       arteries


Misplaced Figures. In the article                                                              Middle
“Nontraumatic Subarachnoid Hem-                                                               cerebral
                                                                                               artery
orrhage and Ruptured Intracranial
Aneurysm: Recognition and Evalua-
                                                                                              Posterior
tion” (October 2023, p. 386), the images                                                     communi-
in the left column of Figure 2 (p. 389)                                                     cating artery
were placed incorrectly, resulting in
the accompanying figure legends being                                                        Vertebral
                                                                                              arteries
placed by the wrong images. Figure 2 is
reprinted here, and the online version
of the article has been corrected. ■                        Middle cerebral artery or poste-
                                                            rior communicating artery (20%)                           Sylvian fissure


                                            Common locations of intracranial aneurysms with approximate incidence
                                            and location on imaging where blood collects.
                                            Illustrations by Dave Klemm.
                                            Information from references 16, 17, and 21.




106 American Family Physician                               www.aafp.org/afp                               Volume 109, Number 2 ◆ February 2024
